Future Icon and Amar Pharma Signs MoU

Industry: Healthcare & Pharma, Hospital, Clinic & Diagnostic
Company: Future Icon Limited, My Pharma Limited
Company Intelligence Tag: Business Insights

In a groundbreaking development for the healthcare sector, Future Icon Limited and Amar Pharma Limited, a prominent medicine supply and healthcare service provider, signed a momentous memorandum of understanding (MOU) on 20 July, 23. The signing ceremony, held at the office of Future Icon Limited, marked a significant step towards strengthening collaboration and enhancing healthcare services. Present at the event were the CEOs of both organizations alongside other key representatives who played instrumental roles in finalizing the agreement.

According to the agreement, all members of Amar Pharma Limited will receive exclusive special benefits and discounts from Future Icon Limited, aiming to improve healthcare accessibility and quality of services. The event highlighted the shared vision of both companies in addressing healthcare emergencies and providing innovative solutions to medical challenges. Amar Pharma Limited, established in 2021 amidst the COVID-19 pandemic, swiftly became a leading player in the industry by catering to the urgent medicine supply needs. Starting in the Mirpur DHHS area, the company rapidly expanded its services to various regions and institutions across the nation.

Source for more details:

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here